An emerging theme in DS research is that individuals with DS could benefit from therapeutic strategies that diminish chronic, hyperactive IFN signaling (Sullivan et al., 2017; Tuttle et al., 2020; Waugh et al., 2023). The gene discussed is IFNA1; the disease is Dravet syndrome.